Skip to main content
News

Tisotumab Vedotin Improved Overall Survival Among Patients With Recurrent or Metastatic Cervical Cancer

Results From the Global, Phase 3 innovaTV 301 Trial 

Stephanie Holland 

According to a press release from Seagen and Genmab, results from the global, phase 3 innovaTV 301 trial have demonstrated that tisotumab vedotin improved overall survival (OS) compared to chemotherapy alone among patients with recurrent or metastatic cervical cancer who experienced disease progression on or after front-line therapy. 

In this open-label study, 502 patients with recurrent or metastatic cervical cancer who received no more than 2 prior lines of systemic therapy in the recurrent or metastatic settings were randomized to receive either tisotumab vedotin or investigator’s choice of chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed). The primary end point was OS and secondary end points included investigator-assessed progression-free survival (PFS), objective response rate (ORR), time to response, and duration of response (DOR). Researchers additionally observed safety and quality of life outcomes. 

At interim analysis, the trial met its primary end point of OS, and an Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary. The key secondary end points of investigator-assessed PFS and ORR demonstrated statistical significance. Additionally, the safety profile was consistent with the known safety profile, as presented in the US prescribing information, and no new safety signals were observed. 

These positive results build upon results from the innovaTV 204 trial, which were the basis of the 2021 accelerated approval of tisotumab vedotin for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. These results may support US accelerated approval and global regulatory application in this indication.

An extension study has been initiated in China and continues to enroll patients. Full results will be presented at an upcoming medical congress and will be discussed amongst US regulatory authorities. 

Source: 

Seagen and Genmab announce TIVDAK® (tisotumab vedotin-tftv) improved overall survival in patients with recurrent or metastatic cervical cancer compared with chemotherapy alone. News Release. Businesswire. September 4, 2023. https://www.businesswire.com/news/home/20230903632820/en/Seagen-and-Genmab-Announce-TIVDAK%C2%AE-tisotumab-vedotin-tftv-Improved-Overall-Survival-in-Patients-With-Recurrent-or-Metastatic-Cervical-Cancer-Compared-With-Chemotherapy-Alone